8-K filing — SRX Global Inc. (SRXH)
Filed: 2026-08-19 AccNo: 0001493152-26-039162 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
SRX HealthSolutions Q3 EPS $(0.36) Up From $(44.51) YoY, Sales $3.392M Up From $2.673M YoY
SRX HealthSolutions (AMEX:SRXH) reported quarterly losses of $(0.36) per share. This is a 99.19 percent increase over losses of $(44.51) per share from the same period last year. The company reported $3.392 million in
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 8:09 PM
- Checked
- Aug 13, 2026, 8:09 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SRX HealthSolutions Q3 2026 Earnings Call: Complete Transcript
On Thursday, SRX HealthSolutions (AMEX:SRXH) discussed third-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzingaSRX Global Acquires Stake In Vistagen Therapeutics; Deal Terms Were Undisclosed
The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.
Read original at benzinga